GlassScriptPhysician profile
Emily P Neely
NPI 1598812455
$20,629.63
in general payments reported to CMS, 2019-2025
56 companies · $3,089 in 2025
The $3,089 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,225 · 2020: $2,695 · 2021: $3,177 · 2022: $3,135 · 2023: $3,126 · 2024: $3,183 · 2025: $3,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,398.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,329.67 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $2,610.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $2,221.57 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $1,670.12 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $875.26 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $813.20 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $738.08 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $715.00 | 2019-2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $559.09 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $543.90 | 2019-2024 | Korlym |
| Ibsa Pharma INC. | $542.54 | 2020-2025 | Tirosint, Licart, Tirosint |
| Mannkind Corporation | $496.48 | 2019-2025 | Afrezza |
| Insulet Corporation | $467.99 | 2019-2025 | Omnipod |
| Cequr Corporation | $440.77 | 2023-2025 | Cequr Simplicity |
| Dexcom, INC. | $341.99 | 2020-2025 | Dexcom G6 Transmitter |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Neely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.